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Introduction
Discovering the genetic cause for human disease, while often   
a notable accomplishment, can be akin to a scientific birth   
announcement—a new name with a future that has more potential 
than promise. New disease genes and pathogenic mutations often 
seem far afield from the overt manifestations of human pathology, 
in particular when the gene is expressed life long, but the disease 
emerges only after years or decades. The journey from defining 
genetic etiology to molecular understanding of disease mecha-
nism can be frustratingly slow, requiring exploration of how muta-
tions alter functions of the encoded protein and delineation of the 
responses that they trigger in relevant cells. Although biochemical 
and biophysical assays and cell biology experiments advance 
these insights, full elucidation of the pathophysiology caused by 
human disease requires a broader approach, including assessment 
of the impact that cells with a pathogenic mutation have on neigh-
boring cells that do not express the mutant protein and consid-
eration of system-wide responses to a diseased organ. Clinical 
information from affected patients can inform these responses, 
albeit with the added complexity of influence from individual 
genomic variation and life styles. A complementary approach, 
which we discuss here, is to invest in the development of animal 
models that are engineered to carry human pathogenic mutations 
on a single genetic background in a controlled environment.
Sarcomere gene mutations cause 
hypertrophic cardiomyopathy (HCM)
HCM is a primary genetic disorder of the heart muscle, the lead-
ing cause of nonviolent sudden death in young adults, and the 
most common cause of sudden death in athletes in the US (Maron 
et al., 1996; Maron, 2004, 2010; Ho, 2010). The prototypic ana-
tomical feature of HCM is left ventricular hypertrophy (LVH), 
which is usually asymmetric, with greater involvement of the   
interventricular septum than the left ventricular–free wall (Fig. 1,   
A and B). LVH is caused by an increase in myocyte size, but not 
myocyte number, and by a greater amount of myocardial fibrosis, 
which is distributed throughout the interstium and in discrete foci. 
HCM myocytes also have distorted nuclei, disorganized myofi-
brils, and abnormal registration of adjoining myocytes, which 
combined with increased fibrosis, contributes to a remarkable 
and characteristic cardiac histopathology (Fig. 1, C and D). These 
anatomical  manifestations  adversely  impact  diastolic  function 
(cardiac relaxation), the quintessential pathophysiologic abnor-
mality observed in HCM that accounts for patient symptoms and 
contributes to adverse outcomes: arrhythmias that predispose to 
sudden cardiac death and progression to heart failure.
HCM is caused by a dominant mutation in one of eight genes 
that encode protein components of the sarcomere (Fig. 1 E; 
Seidman and Seidman, 2011). Sarcomeres are the fundamental 
unit of contraction and are composed of thick (myosin) and thin 
(actin) filaments that slide past each other and produce force 
(Solaro, 2010). With depolarization of myocytes, calcium enters 
through the voltage-gated L-type Ca
2+ channels on the mem-
brane and activates release of stored calcium from the sarco-
plasmic reticulum (SR) through the cardiac ryanodine (RyR2), 
a process termed calcium-induced calcium release. Increased 
cytosolic calcium binds troponin C, produces conformational 
changes in the troponin complex, and displaces tropomyosin 
from the actin–myosin interactive sites. Myosin binds actin and 
results in formation of cross-bridges, and with hydrolysis of 
ATP by myosin, energy propels myosin sliding along actin fila-
ments. The resultant force is transmitted to the sarcolemma and 
extracellular matrix. Upon rebinding of ATP, myosin releases 
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Hypertrophic cardiomyopathy (HCM) is a common inher-
ited heart disease with serious adverse outcomes, including 
heart failure, arrhythmias, and sudden cardiac death. The 
discovery that mutations in sarcomere protein genes cause 
HCM has enabled the development of mouse models that 
recapitulate clinical manifestations of disease. Studies in 
these models have provided unexpected insights into the 
biophysical and biochemical properties of mutated con-
tractile proteins and may help to improve clinical diagno-
sis and management of patients with HCM.
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(Colson et al., 2010). With the exception of some MYBPC3 
mutations, all HCM mutations encode missense residues that 
substitute only one amino acid in a sarcomere protein. The 
discovery of genetic causes for HCM posed a new enigma—
how does a subtle change in one protein component of the 
multimeric sarcomere produce the profound histopathology 
and symptoms of HCM?
Modeling HCM in mice
The absence of adult ventricular myocyte cell lines has precluded 
many strategies to delineate the impact of HCM mutations on 
myocyte structure and function. To overcome this issue, several 
teams engineered HCM mutations into mice. Our group modeled 
human  myosin mutations that are associated with severe human 
phenotypes by introducing missense mutations (MHC
Arg403Gln, 
MHC
Arg453Cys, and MHC
Arg719Trp; Geisterfer-Lowrance et al., 1996; 
Debold et al., 2007; Teekakirikul et al., 2010) into the endoge-
nous cardiac  myosin heavy chain gene. Cardiac  and  myosin 
isoforms are reciprocally expressed during development and 
across species. In humans, the  isoform predominates during 
embryogenesis, and the  isoform predominates in postnatal 
life, whereas in mice, the opposite pattern occurs. Myosin isoforms 
share 93% amino acid identity, and although their functions in 
the sarcomere are identical, biophysical and biochemical differ-
ences have been described. Despite these issues and differences 
in cardiac physiology between these species, mice carrying human 
mutations recapitulate many important aspects of HCM.
Young mutant mice show neither LVH nor histopathol-
ogy (denoted as prehypertrophic), mirroring the quiescent phase 
in children with HCM mutations and normal cardiac dimensions. 
After pubescence, there is insidious emergence of disease, and 
adult mutant mice have pathological hallmarks of HCM, includ-
ing LVH, myocyte disarray, and increased amounts of myocar-
dial fibrosis (Geisterfer-Lowrance et al., 1996; Wolf et al., 2005; 
Teekakirikul et al., 2010).
Primary isolates of myocytes from HCM mice show 
multiple intrinsic abnormalities. Mutant myocytes have higher 
end-systolic and end-diastolic stiffness and slower relaxation 
dynamics compared with myocytes isolated from wild-type lit-
termates (Chuan et al., 2012). Surprisingly, mutant myosins 
isolated from HCM mice exhibit increased active force genera-
tion, increased ATP hydrolysis, and faster actomyosin sliding 
velocities in comparison to wild-type myosins (Tyska et al., 
2000; Debold et al., 2007; Chuan et al., 2012). Together, these 
data suggest an unexpected conclusion: that HCM mutations 
increase the biophysical properties of myosin. As such, LVH 
in HCM does not seem to be a compensatory response to in-
adequate contractile force production but instead a direct response 
to HCM mutations.
HCM mutations’ impact on myocyte biology extends be-
yond the sarcomere. Analysis of the mutant mice reveals that 
an early consequence of a mutant contractile protein is a per-
turbation of calcium cycling (Fatkin et al., 2000). Although 
the mechanism that accounts for this is unclear, there is some 
evidence suggesting that mutant sarcomeres retain calcium for 
longer times than normal (Sweeney et al., 1994; Lankford et al., 
1995; Spindler et al., 1998; Marston, 2011).
actin, and calcium recycles back to SR via an ATPase-dependent   
pump (sarco/endoplasmic reticulum Ca
2+-ATPase) or is extruded 
via the Na
+/Ca
2+ exchanger, whereas troponins T and I and tropo-
myosin rebind actin, blocking myosin interactions, collectively 
resulting in muscle relaxation.
More than 50% of HCM mutations occur in MHY7, which 
encodes  cardiac myosin heavy chain, or MYBPC3 (Seidman 
and Seidman, 2011), which encodes myosin binding protein C,   
a phosphorylatable molecule that regulates sarcomere con-
traction by affecting the likelihood of cross-bridge binding 
Figure 1.  Cardiac manifestations and genetic causes of HCM. (A and B) In   
comparison to the normal heart (A), the HCM heart (B) shows LVH with 
increased thickness of the walls and papillary muscles. Bars, 1 cm. The 
image in A is reprinted from Wang et al. (2010) with permission from   
Annals of Internal Medicine. (C and D) In comparison to normal myocar-
dial histology (C), HCM (D) shows misaligned myocytes with enlarged 
nuclei and expanded interstitial matrix (light pink). Hematoxylin and eosin 
stain. (E) A schematic of the sarcomere showing the major contractile pro-
teins that are mutated in HCM.419 Hypertrophic cardiomyopathy • Teekakirikul et al.
through to the expected development of overt disease with neutral-
izing antibodies that target all three Tgf- isoforms. Blocking 
Tgf-  signaling  significantly  diminished  nonmyocyte  prolif-
eration, reduced expression of downstream targets of Tgf- ac-
tivation, and resulted in less hypertrophy and histopathology. 
Additional experiments have indicated that Tgf- activates the 
canonical Smad-dependent pathway in HCM mice (Teekakirikul 
et al., 2010).
To consider whether this strategy could be adapted for   
human translational experiments, we assessed a pharmacological 
approach to diminishing Tgf- signals in HCM mice. The pep-
tide hormone angiotensin II increases cardiac fibrosis via acti-
vating Tgf- signals (Porter and Turner, 2009) and blockade of 
the angiotensin II type I receptor by the antagonist losartan,   
a  Food  and  Drug  Administration–approved  antihypertensive 
drug, blocks Tgf- activation and reduces circulating levels (Matt 
et al., 2009). Losartan administered to prehypertrophic mice 
and continued throughout life showed benefits comparable with 
Tgf- neutralizing antibodies: treatment extinguished periostin 
expression and nonmyocyte proliferation and reduced LVH and 
HCM histopathology that emerged in untreated mutant mice. 
Early pharmacologic intervention was critical; administration 
of losartan to mice with established HCM was unable to reverse 
hypertrophy or fibrosis (Teekakirikul et al., 2010).
These studies raise many important and unanswered ques-
tions. What triggers increased Tgf- activation early in the course 
of HCM? Does Tgf- activation account for myocyte hypertro-
phy? By what mechanisms do HCM myocytes increase Tgf- 
activation in nonmyocytes? An enticing theory that addresses 
some of these questions links the enhanced biophysical proper-
ties of HCM sarcomeres (Tyska et al., 2000; Chuan et al., 2012) 
to the transcriptional activation of Tgf- (Fig. 2). A previous 
study demonstrates that ex vivo cultures of myocytes isolated 
from wild-type mice, when subjected to mechanical stretch, in-
crease Tgf- expression above levels found in quiescent myo-
cytes (Ruwhof et al., 2000). Similarly, isolated nonmyocyte cells 
subjected to stretch activate Tgf- expression (van Wamel et al., 
2002). Perhaps the greater biomechanical forces produced by 
HCM mutant sarcomeres in myocytes and transmitted to non-
myocytes increase Tgf- expression that activates a profibrotic 
program in HCM hearts. With the expansion of the extracellu-
lar matrix–surrounding myocytes, relaxation would be further 
impaired, and myocyte metabolic demands and cellular stress 
would  increase,  resulting  in  Mef2  activation  and  ultimately 
myocyte death and focal myocardial scarring. Recurrence of 
this life-long scenario could contribute to the LVH and HCM 
histopathology and promote progressive symptoms in patients.
Translation of basic insights into clinical 
studies of HCM
Discovery of the genetic cause for HCM combined with robust 
high-throughput sequencing platforms has enabled a cost-effective 
gene-based diagnosis for HCM. Comprehensive sequence analy-
ses of all HCM genes in an affected individual can identify the 
pathogenic mutation and define mutation carrier status in all at-
risk family members. As HCM is a dominant disorder, 50% of 
first-degree relatives of affected individuals are predicted to carry 
Biochemical and biochemical properties of HCM myocytes 
also impair relaxation. Myosins extracted from MHC
Arg403Gln 
mice have enhanced affinity for actin within tropomyosin– 
troponin–actin complexes (Palmer et al., 2008), an inter-
action that is expected to exert drag on actin filaments during 
relaxation and would impair diastolic relaxation (Chuan et al.,   
2012).  Delayed  calcium  reuptake  into  the  SR  also  delays   
relaxation and might activate calcium-dependent signals that 
promote changes in myocardial architecture. The transcription 
factor Mef2 (myocyte enhancer factor-2) is increased in HCM, 
particularly in myocytes that reside near microscopic foci of 
necrosis and fibrosis (Konno et al., 2010). Activation of Mef2 
occurs  via  calcium-dependent  CaMKII  (calcium/calmodulin-
dependent protein kinase II) phosphorylation and serves as a 
molecular marker of myocyte stress (Kim et al., 2008). Local-
ized  Mef2  expression  predestines  premature  death  of  HCM   
myocytes (Konno et al., 2010) and the subsequent accumulation 
of myocardial fibrosis.
Transcriptional activation of Tgf- signaling 
in mouse HCM
Myocardial fibrosis (increased numbers of nonmyocyte cells 
and amounts of extracellular matrix proteins) is a pathological 
hallmark of HCM that correlates with the degree of hypertrophy, 
impaired ventricular performance, diastolic dysfunction, and 
increased energy consumption. Myocardial fibrosis contributes 
to progressive heart failure and may increase risk of arrhyth-
mias and sudden cardiac death (Basso et al., 2000; Choudhury 
et al., 2002). The molecular events involved in the accrual of 
myocardial fibrosis in HCM has been enigmatic, especially be-
cause nonmyocyte cells (presumptive cardiac fibroblasts) that 
are involved in fibrosis do not express sarcomere proteins and 
are therefore not directly impacted by HCM mutations.
To  define  transcriptional  responses  to  HCM  mutations 
that increase cardiac fibrosis, we used next generation sequenc-
ing technologies to compare RNAs expressed in nonmyocyte 
cells isolated from wild-type and HCM mice (Teekakirikul et al., 
2010). Surprisingly, >1,500 RNAs that are enriched in nonmyo-
cyte cells are altered by a sarcomere gene mutation. Functional 
annotation of transcripts with increased expression showed sig-
nificant overrepresentation (P < 0.05) of gene ontogeny terms 
related to the extracellular matrix, cell cycle, and cell prolifera-
tion, including significantly increased expression (P < 0.0001) 
of transcripts that encode fibroblast proteins. Notably, the ex-
pression of RNAs encoding Tgf-1 and 2, periostin, collagen, and 
connective tissue growth factor was increased, both in nonmyo-
cyte cells isolated from prehypertrophic MHC
Arg403Gln mice (Kim 
et al., 2007) and in mice with overt hypertrophy (Teekakirikul 
et al., 2010). As these molecules exacerbate extracellular matrix 
production and promote fibrosis in other pathologies, increased 
expression  of  proteins  by  nonmyocyte  cells  in  HCM  hearts 
would be expected to increase myocardial fibrosis.
To evaluate the role of profibrotic molecules in the emer-
gence of HCM, we initially examined MHC
Arg403Gln mice bred 
onto a periostin-null background (Oka et al., 2007). Fibrosis in 
these compound mutant mice was reduced but not extinguished. 
Next, we treated HCM mice from the prehypertrophic phase JCB • VOLUME 199 • NUMBER 3 • 2012   420
cardiac performance will provide new therapeutic opportunities.   
A clinical trial to assess the safety and efficacy of pharmacologic 
inhibition of Tgf- signaling in HCM is in development, but 
additional strategies to address more proximal consequences of 
sarcomere gene mutations are needed. There are new oppor-
tunities to modulate the release of SR calcium, by stabilizing 
the RyR2 channel and interacting proteins (Shan et al., 2010). 
Whether these can be exploited to improve calcium cycling in 
HCM warrants consideration. The most direct approach would 
be to directly target sarcomere function—a daunting but feasible 
task, given the recent study of a small molecule that increases 
myosin activity (Malik et al., 2011). Identification of molecules 
that attenuate the increased biophysical properties of sarcomere 
mutations would directly address the primary defect in HCM 
and  potentially  abrogate  the  myriad  of  downstream  signals 
that underpin HCM pathophysiology. Continued basic studies 
of sarcomere gene mutations can be expected to uncover other 
strategies to limit symptoms and improve outcomes in HCM 
and as well to increase knowledge of cardiac muscle biology.
This work was supported in part by grants from the Howard Hughes Medical 
Institute (to C.E. Seidman), the National Institutes of Health, and Leducq 
the same pathogenic mutation. Clinical evaluations of mutation 
carriers can reveal occult HCM in asymptomatic adults and/or 
normal cardiac morphology in young “preclinical” individuals, 
in whom disease has not yet emerged. Recent detailed imaging 
experiments and serum biomarkers of preclinical mutation carriers   
(Ho et al., 2010) recapitulate seminal observations made in   
experimental models of HCM. Before the onset of hypertrophy, 
preclinical mutation carriers have increased systolic contraction 
and diminished relaxation, analogous to increased enhanced bio-
physical properties of isolated mutant myosins and increased stiff-
ness in myofilament preparations with HCM mutations. Direct   
assessment of Tgf- activation has not been undertaken in   
human HCM, but both preclinical mutation carriers and HCM 
patients have significantly higher than normal levels of circulating 
C-terminal propeptide of type I procollagen, a protein associated 
with increased collagen synthesis and fibrosis (Ho et al., 2010).
Next step—HCM therapeutics
The concordance between human and mouse HCM studies   
provide strong evidence that fundamental understandings of   
how HCM alters sarcomere function, myocyte biology, and 
Figure 2.  A model by which sarcomere protein mutations cause HCM histopathology. Sarcomere proteins containing HCM mutations (purple) exhibit 
enhanced biophysical properties of the contractile apparatus and delayed calcium reuptake into the SR. Increased mechanical forces of HCM myocytes, 
and perhaps calcium-dependent signals, are transmitted to the surrounding nonmyocyte cells and activate transcriptional responses. Transcriptional activa-
tion of Tgf-–dependent signals in nonmyocyte cells promotes proliferation and secretion of profibrotic molecules, which expand the extracellular matrix. 
Both the intrinsic biophysical properties of mutant sarcomeres and the extrinsic strain imposed by the increased amounts of fibrosis augment myocyte stress 
(evident by increased Mef2 expression) and promote early myocyte death and subsequent focal scarring. The expanded interstitium and foci of scars 
perturb myocardial histology and contribute to LVH (Fig. 1, B and D). The interrelated pathophysiology that results from HCM mutations poses several 
potential therapeutic opportunities. Small molecules that directly target the sarcomere and attenuate the enhanced biophysical properties caused by HCM 
mutations would be expected to diminish downstream deleterious signals. A less direct approach would be to capitalize on pharmacologic agents that 
impact myocyte calcium cycling and/or that inhibit Tgf- activation so as to limit myocardial fibrosis.421 Hypertrophic cardiomyopathy • Teekakirikul et al.
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